Amgen tests monthly obesity treatment with MariTide in Phase 3

The Tip Desk · September 23, 2026 · 2 min read

The investigational therapy combines GLP-1 activation with GIP blockade; durability and tolerability remain central questions.

Maridebart cafraglutide, known as MariTide or AMG 133, combines GLP-1 receptor agonism with GIP receptor antagonism. That distinction matters: it should not be described as the same dual-agonist mechanism as tirzepatide or VK2735. Amgen is investigating monthly or less frequent dosing. A proposed reduction in injection frequency is a development objective, not proof of better adherence.

A central Phase 3 study in adults with obesity or overweight without type 2 diabetes compares subcutaneous treatment with placebo and measures weight change at 72 weeks. Its registry state is active but not recruiting. The broader program includes separate cardiovascular and sleep-apnea studies, which should remain distinct from the weight-management study when interpreting future results.

The important unanswered questions include the balance of weight effects, gastrointestinal tolerability, discontinuation and durability under less frequent dosing. Mechanistic novelty and an extended interval do not establish superiority over approved products. This account does not assign a verified date to the next Phase 3 readout or infer approval likelihood from the development stage.

Amgen’s operating cash generation and debt provide context for a large development program, but the filing does not earmark a portion of group cash for MariTide. Future financial or partnership changes should enter the compound history only when they materially affect the program.

Amgen reported $13.989 billion of cash and equivalents at June 30, $5.445 billion of current debt and $51.859 billion of long-term debt. First-half operating cash flow was $6.191 billion, with net income of $4.194 billion. Revenue reached $10.054 billion in the second quarter and $18.672 billion for the first half. This is an established commercial business funding a broad pipeline while carrying substantial debt. Its corporate liquidity should not be described as cash specifically committed to MariTide.